Myoview (Tetrofosmin)

Tetrofosmin is first labeled with technetium‑99m, creating a lipophilic cationic complex that readily enters myocardial cells. Its uptake is proportional to regional blood flow, and it becomes trapped within the mitochondria. The resulting distribution of radioactivity mirrors perfusion, allowing SPECT cameras to generate detailed images of myocardial blood flow and tissue viability.

The administered activity of Myoview is determined by the prescribing physician or nuclear medicine specialist based on patient weight, the imaging protocol, and regulatory guidelines. Typical adult dosing ranges are defined in the product’s prescribing information, but exact numbers are set individually and should not be altered without professional supervision.

Safety data for Myoview in pregnant or nursing women are limited, and the radiotracer delivers ionizing radiation that could affect a fetus or infant. Use is generally avoided unless the diagnostic benefit outweighs the potential risk. If administration is deemed essential, the prescriber should follow local radiation safety guidelines and consider alternative imaging modalities.

To order Myoview, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details (including cold‑chain logistics if required) and assists with any necessary import documentation.

Myoview (technetium‑99m tetrofosmin) and technetium‑99m sestamibi are the most commonly used perfusion tracers, offering similar image quality and radiation dose. Compared with thallium‑201, tetrofosmin provides higher photon energy, allowing better image resolution and shorter acquisition times, while also having a lower radiation burden. Choice of agent often depends on local protocol, availability and physician preference.

Myoview must be stored refrigerated at 2 °C to 8 °C in its original packaging, protected from light. The kit should not be frozen or shaken, and any unused portion should be discarded according to local regulations for radioactive materials. Handling requires trained personnel wearing appropriate protective equipment and following radiation safety procedures.

Myoview is supplied as a sterile radiopharmaceutical injection kit that is reconstituted with technetium‑99m per the manufacturer’s instructions. The prepared solution is administered intravenously, typically as a rapid bolus injection, under the supervision of a qualified nuclear medicine physician or technologist. Imaging is performed shortly after injection, according to the selected stress or rest protocol.

The most serious risks associated with Myoview include severe allergic reactions such as anaphylaxis, significant hypotension or cardiovascular collapse, and cardiac arrhythmias that may arise during the stress phase of the study. Additionally, radiation exposure, while low, can cause skin injury at the injection site if dosing guidelines are not followed. Immediate medical attention is required if any of these events occur.

Myoview should be avoided in patients with known hypersensitivity to tetrofosmin, technetium‑99m, or any kit excipients. It is also contraindicated in pregnant women unless the diagnostic benefit justifies the radiation risk, and in nursing mothers who cannot discontinue breastfeeding. Patients with severe uncontrolled thyroid disorders, recent iodine or perchlorate therapy, or those unable to tolerate pharmacologic stress agents should be evaluated carefully before use.